A c c e p t e d M a n u s c r i p t 2 Highlights  We systematically reviewed the socioeconomic cost literature for 10 rare diseases.
M a n u s c r i p t
Introduction
Most rare diseases are associated with high unmet need due to the lack of available and effective treatments and the relative lack of research to discover and develop such treatments. In the European Union (EU), a rare disease is defined as one affecting less than 1 in 2,000 people, and it is estimated that over 6,000 different, life-threatening or chronic, rare diseases exist today (1). Although rare diseases are by definition associated with low prevalence, considering that 6% -8% of the population are affected by a rare disease, the total number of patients in the EU is estimated to be between 27 and 36 million (2) . With the majority of rare disease patients suffering from less frequent conditions with a prevalence of 1 in 100,000 population, and with many rare diseases being of genetic origin, there is a strong public health interest relating to their cost and broader socioeconomic impact in order to develop sustainable health policy options.
Cost-of-illness (COI) studies measure the socio-economic burden of a disease and can be used as a public policy tool to assist in prioritization and justification of healthcare and prevention policies (3) . COI studies can indicate which interventions are more valuable by comparing averted economic burden, and consequently lead to shifts in distribution of public and private investments. Different stakeholders can utilise COI studies differently. Governments can estimate the financial impact of a disease on public budgets for resource allocation purposes, whereas pharmaceutical corporations can identify diseases with high management costs to direct research and development (R&D) investments towards accordingly.
In addition, COI studies provide information for other types of economic evaluations, including a framework for cost estimation in cost-utility and cost-effectiveness analyses, frequently used by policy makers (3, 4) . They are increasingly cited in clinical and epidemiological research to emphasize the importance of studying a particular disease and the scale of a problem, conveying the aggregate burden of illness on society by estimating the maximum amount that could potentially be saved if a disease were to be eradicated (5, 6 ).
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While COI studies can identify and measure all costs of a particular disease, they do not address issues of inefficiency or waste, or weigh up costs and benefits of interventions (6) . Caution is also advisable when interpreting COI estimates as potential savings if a disease were systematically targeted, as not all conditions can be fully eradicated, and some proportion of economic burden will remain despite effective interventions (6) .
For optimal resource allocation, COI studies should be used in combination with full economic evaluations such as cost-benefit or cost-utility analyses which assess both costs and outcomes (7) .
COI studies employ a wide range of different designs and methodologies, often limiting comparability and usefulness of results (8) . Variations include data sources, perspectives (healthcare, societal, etc.), cost types, costing approach and discount rate (9) . While standardisation of methodology through implementation of guidelines is becoming increasingly important, some flexibility may be required for diseases with special characteristics to be adequately described (3, 9) .
Numerous COI studies have been conducted over the past three decades across a range of diseases, however few have addressed rare diseases. In this context, the aim of the BURQOL-RD project ("Social Economic Burden and Health-Related Quality of Life in patients with Rare Diseases in Europe") was to provide new tools and knowledge for 10 rare diseases (RDs), including socio-economic burden and health related quality of life for patients and their caregivers (10) .
The objective of this study is to systematically review the relevant literature on the socioeconomic burden of RDs and identify all costs, both direct and indirect, related to ten specifically identified RDs from the perspective of patients, families and society.
Data and methods
The BURQOL-RD project participants adopted a Delphi consensus approach in combination with a Carroll diagram for the selection of the 10 RDs to be studied (10) .
An expert panel involved 23 individuals as representatives of each associated and collaborating project partner. Initially, the selection criteria for the potential RDs were defined and were summarised under the acronym BOSCARE: these included a Broad spectrum of RDs should be suitably represented, including some ultra-rare and less A c c e p t e d M a n u s c r i p t 6 frequently researched RDs; the availability of strong and well-Organised patient associations for specific RDs in most participating Member States ensuring adequate recruitment and participation rates; taking advantage of previous Studies carried out by Eurordis and other national/regional associations, to consider at least some of the RDs included in such studies for which a minimum threshold of participation was obtained;
select RDs where in the absence of effective therapies a professional network can offer integrated advice, CAre and support for the affected families; and availability of rare disease REgistries, European research networks financed by the European Union DGSanco or networks of reference centres. Subsequently, a two-round Delphi panel process yielded a prioritised list of diseases. A questionnaire was administered to all experts via e-mail. In the first round, the questionnaire offered the BOSCARE criteria and an initial set of candidate RDs; each expert was asked to select 10 diseases according to the BOSCARE criteria and rank them by importance. In the second round, members were provided with their own rankings as well as with the overall results of the first round for the panel, and a revision of their ranking was requested. Based on this approach a shortlist of 36 RDs emerged following the end of the first round, and a total of 33 RDs were shortlisted following the end of the second round. The following step involved a joint discussion among the expert panel, where six potential determinants were identified, notably (a) prevalence of ≥1/10,000 or <1/10,000; (b) age at onset and whether this was during adulthood or childhood; (c) the extent to which the disease was genetic or had other origin; (d) whether or not the disease resulted in physical impairment and/or mental impairment; (e) whether or not there exist valid diagnostic tests; and (f) whether or not there is availability of effective therapies to modify the disease course. Experts provided a ranking for the conditions based on these determinants. Finally, in the group of shortlisted conditions from the above step, a Carroll trilateral diagram was applied taking into account three determinants, namely (a) prevalence, (b) availability of effective treatments and (c) need for carer. 
Histiocytosis and Epidermolysis Bullosa (EB). In selecting the final list of RDs for this
A c c e p t e d M a n u s c r i p t 7 project, efforts were made to include both rare and ultra-rare diseases review as well as diseases that did have some pharmacological treatment versus diseases that did not.
Based on the agreed-upon disease sample, a systematic literature review of COI was undertaken using the following five keywords in conjunction with the names of the 10 RDs identified above: cost of illness; spending; financial expenditure; financial burden; costs.
PubMed and the Web of Science (WoS) databases were searched in March 2011. All studies published prior to this date were eligible for inclusion. The resulting studies were filtered to identify their suitability for inclusion based on whether they provided evidence of costs, both direct (either medical or non-medical related)_and indirect (i.e. productivity loss).
All costs were converted to 2010 Euros (€). Given the limitations of the European
Central Bank (ECB) Statistical Data Warehouse (does not provide currency conversion rates before 1999, which is later than some of the cost figures identified and, additionally, it does not cover European currencies prior to their accession to the Euro), exchange rates were retrieved using the PACIFIC Exchange Rate Service from the University of British Columbia (monthly averages, price notation)(11). Prices were adjusted to 2010 levels before conversion using Average Consumer Price Inflation figures (12) . <Figure 1 about here>
Results

Disease characteristics and prevalence in Europe
By reviewing the available evidence on disease characteristics and their prevalence/rarity, a better understanding of the burden of the different diseases can be gained. In turn, the limited availability of COI evidence suggests the need for further research on the selected RDs. Prevalence for each disease is shown on Table 1 .
A c c e p t e d M a n u s c r i p t 8 CF is the most frequent pediatric autosomal recessive disease in Caucasian populations (13) (14) (15) , occurring in 1 in 2,500 to 3,600 births, with a European Union (EU) prevalence of 12.6:100,000 population (16) . CF causes abnormalities in chloride ion transportation resulting in increased viscosity of mucus secretions within numerous organ systems.
This impacts primarily the lungs and respiratory function, the pancreas, fat digestion, and, over the long-term, liver function. Respiratory failure is the primary cause of morbidity and mortality in CF patients (17) . The disease was originally considered pediatric as most did not survive past adolescence, however, improvements in daily routines, medical management and pharmacological support have allowed increasing numbers of patients to survive until middle adulthood.
DMD is a recessive X-linked type of muscular dystrophy, affecting boys only. The condition appears in early childhood, resulting in muscle degeneration affecting mobility, spinal development and breathing. Life expectancy ranges from teenage to early adulthood. Treatment is largely supportive via physical therapy and medical appliances and home modifications, although some clinical trials are being performed on beta-agonists. The condition affects approximately 1 in 4,000 male infants (18) , with an EU prevalence of 5 per 100,000 population (16) .
Fragile X syndrome (FXS), otherwise known as Martin-Bell syndrome or Escalante's syndrome, is an X-linked dominant genetic disorder resulting primarily in autism and other mental disability (19). The prevalence of the disease is 1:3,600 males and 1:4,000-6,000 females (20) and the EU prevalence is estimated to be 20 per 100,000 population (16) .
Haemophilia is a recessive X-linked disorder resulting in lowered clotting factors, which prevent coagulation and clotting from occurring. This causes difficulties in maintaining a blood clot to start the healing process and causes bleeding to last for longer. There are three types: haemophilia A, B and C (autosomal) with poorly functioning clotting Factor VIII (80% of patients), IX (20% of patients) and XI respectively. Treatment involves regular infusions of Factors VIII, IX or XI from human or recombinant blood products.
The incidence of haemophilia A varies by country at 1:5,000-10,000 males while haemophilia B is 1:20,000-34,000 males (21), with an overall haemophilia prevalence in the EU at 7.7 per 100,000 population (16) . Haemophilia has been divided into three M a n u s c r i p t 9 levels of severity -mild (5-40% clotting factor), moderate (1-5%) and severe (<1%).
Treatment with clotting factor VIII or IX may result in the production of antibodies, known as inhibitors, causing standard treatment to become ineffective and bleeding more difficult to control. More advanced drugs have been developed to treat patients with inhibitors. Further, as treatment involves regular use of blood products, patient are exposed to the risks of Hepatitis C (HCV)/Human Immunodeficiency Virus (HIV) infection, particularly up until the mid-1990s when the virus testing window was large and before the mid-1980s when blood safety was poorer compared with current standards. As a result, a significant number of haemophilia patients are infected with HCV/HIV, making their treatment and management more difficult.
JIA is the most common form of childhood arthritis, primarily affecting knees, ankles, wrists, hand and feet. Chronic pain is commonplace, and over time joints become damaged and contracted resulting in growth retardation (also an effect of long term steroid use). There are three classifications: oligoarticular (≤4 joints in first 6 months; 50% of children), polyarticular (≥5 joints in first 6 months; 40% of children) and systemic (joint and organ involvement; 10% of children). Treatment involves physical therapy, medication (anti-inflammatory drugs, corticosteroid injections, TNF alpha blockers), surgery and occupational therapy. It has an estimated prevalence of children in every 100,000 (22) , and an overall prevalence estimate in the EU at 5.0 per 100,000 population (16) .
MPS is a group of metabolic disorders where the body does not produce sufficient enzymes needed for glycosaminoglycans breakdown (long chains of sugar carbohydrates in the cells aiding bone, cartilage, tendons, corneas, skin and connective tissue growth) and are part of the lysosomal storage disease family. There are a number of MPS types, from MPS I to MPS IX each with varying incidence, sub-types and deficient enzymes (Type I, with prevalence of 1:100,000 to 1:500,000 population; Type II, 1:100,000 to 1:170,000 males; Type III, 1:70,000; Type IV, 1:200,000 to 1:300,000; Type VI, 1:250,000 to 1:600,000)(23-27). In the EU, the overall prevalence for all types of MPS is estimated to be 3:100,000 population (16) . MPS Type I, also known as Hunter's Disease, is commonly differentiated into severe and attenuated types resulting in mental retardation and, often, poor cardiac and liver development. Symptoms are usually apparent early in life, at times as young as one year old (23). MPS Type VI, also M a n u s c r i p t 10 known as Maroteaux-Lamy syndrome, primarily obstructs bone development resulting in short stature, skeletal and joint deformities. While patients with the rapidly progressive phenotype tend to die before adulthood, those with a slowly progressive phenotype may live into their 40s or 50s. Recently, a new treatment, enzyme replacement therapy (ERT) (recombinant human ASB enzyme, rhASB) has been made available, potentially improving patient quality of life (28) .
Scleroderma is a connective tissue disorder resulting in changes in the skin, muscles, blood vessels and internal organs due to a buildup of collagen in these organs. The cause is unknown, however, it does run in some families and some risk factors have been identified, such as industrial exposure to silica dust and polyvinyl chloride. More common in women than men, scleroderma tends to affect individuals between 30 and 50 years of age (29). The prevalence of scleroderma is estimated to be around 74:100,000 among women and 13:100,000 among men (30) , with an overall EU prevalence being 42:100,000 population (16).
Prader-Willi syndrome (PWS) is a congenital genetic disease where seven genes on chromosome 15 are deleted or not expressed. This results in obesity due to hyperphagia, poor muscle tone, sex glands produce little or no hormones, as well as often below average intelligence and learning difficulties (31) . Estimations of the incidence of PWS vary depending on the study and country studied, but it is in the region of 1:22,000 births (32) , with an EU prevalence of 1.6:100,000 population (16) .
Few therapies exist for PWS. Growth hormone therapy (GHT) has been authorized by the FDA for the treatment of children with PWS (33) . The use of physiotherapy, occupational therapy, speech therapy, cognitive therapy and dietetic services is a usual part of treatment to deal with muscle tone, feeding difficulties in infancy, over-eating in childhood, and learning difficulties.
Histiocytosis refers to a group of RDs resulting from an over production of histiocyte, a tissue macrophage part of the mononuclear phagocytic system responsible for tissue destruction and defense. Histiocytosis can be divided into three or more categories EB is part of a group of rare hereditary skin diseases characterized by blisters forming on the skin spontaneously, or following minimal trauma. Due to a mutation in the keratin or collagen gene, the skin is extremely fragile, with 4 major sub-classifications.
Disease severity varies from benign to deadly, with more severe forms affecting the internal gut linings and resulting in poor absorption and chronic malnutrition in addition to skin cancer development (36). The prevalence of EB is 50 children per million births, with no racial or sex prejudices (37) . In the EU, the prevalence is estimated to be 2.4:100,000 population (16) . The pain associated with EB has been described as third degree burns. Recent treatment developments include bone marrow transplants. <Table 1 about here>
Evidence on costs and availability of COI evidence
A total of 1654 article titles were initially screened ( Figure 1 ). Of these, 253 abstracts were retrieved for further investigation. Studies reporting any COI data were included,
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A c c e p t e d M a n u s c r i p t 12 while studies not providing concrete data (e.g. estimates based on similar conditions) were excluded. Cost-effectiveness studies were only included if they reported information on the COI or components of specific types of health care, individual or societal costs. A total of 201 full-text articles were accessed for eligibility (including cited articles), and 77 studies were included in the study. There was an unequal distribution of studies over disease types, with the largest proportion of studies covering CF (n=29) and haemophilia (n=22). For the remaining diseases 0-8 studies per disease were identified, but, overall, COI study availability was limited across most of the study RDs ( Table 2 ). The evidence collected indicates COI data availability in terms of total lifetime costs across four RDs (CF, DMD, FXS, haemophilia), and total annual costs and indirect total costs across five RDs (CF, haemophilia, JIA, histiocytosis, scleroderma). In the sections that follow, we present the available evidence.
<Table 2 about here>
Cystic fibrosis
In total, 29 studies were found to address COI aspects of the disease, making it the most studied disease out of the ten conditions selected. Lifetime treatment costs are estimated to be lower in older studies, as prevention of progression (physiotherapy, high fat diet plus enzymes) and medications (IV therapy) were not yet universally applied. Over twenty years ago Wildhagen et al. calculated Dutch lifetime costs per patient adjusting for survival and using a 5% discount rate to €287,591 (GBP 164,365 in 1991) (38) , while later estimates in Germany based on extrapolation of childhood costs suggested €477,280 (€396,000 in 1997) (15) A c c e p t e d M a n u s c r i p t 13 between these estimates are primarily due to inclusion of only outpatient costs in Germany, while the American study incorporated direct costs including medication and inpatient care (though unclear whether outpatient costs were included).
Per patient average total costs (direct plus indirect) depend on age, ranging from €16,307 at age 1-9 to €68,331 at age 30-39 (DKK94,150 and DKK394,518 in 1998)(42).
Pauly estimated annual indirect costs at €8,814 (US$8,400 in 1996) based on incapacity to work, disability and premature death, corresponding to 60% of estimated direct costs (39) . The highest reported figure was 57% of direct costs attributable to drugs (60) , and the lowest at 9% was recorded in an insurance claims based study from 1994 where inpatient care accounted for the majority of direct costs (59-81%) (61).
Only one study examined 'non-healthcare costs' associated with CF (including nonhospital medical care, domestic help, special facilities etc.), and estimated home-care costs to be approximately 50% of total medical and non-medical lifetime costs. Total average non-hospital costs of care were estimated at €10,826 (GBP6,657 in 1993) (13) .
In other studies, home-care has been estimated to be both significantly more expensive iii In this case, total cost per case is specific to hospitalisation, not to treatment overall. iv Patients were classified as receiving care either at home or in hospital, based on the location in which they received >60% of their treatment, over the course of one year. 
Duchenne muscular dystrophy
Only three studies (the Netherlands, USA and Canada) reported treatment costs of DMD, 
Fragile X syndrome
Only a few of the studies stated which costs were included in lifetime treatment costs. A few (68, 69) 
Haemophilia
In total, 22 studies were found to address COI aspects of the disease, making it the second most studied disease out of the ten, following CF.
Only one study (Mexico) estimated total lifetime discounted (5%) cost of hemophilia and with inhibitors at between €67,221 (€54,226 in 1997) and €231,175 (€186,482 in 1997) depending on whether the patient was a high or low responder (87). Infection with HIV or HCV, apart from clotting factor, is also known to be associated with increased costs for prescription drugs, inpatient-and outpatient services, which is of importance due to the many infections occurring prior to blood screening in the 1980s (88, 89) .
As an external factor, time to treatment has been shown to have a statistically significant upward effect on both total cost and number of doses required for resolution.
As patients generally live further from hospitals than from outpatient clinics, both time to treatment, time to resolution and total cost was 3-4 times higher in hospitals than in outpatient or home treatment settings (90).
Schramm et al. examined costs incurred by patients in both prophylaxis and on-demand
(OD) groups in a multi-country (France, Germany, Italy, Netherlands, Sweden, UK) analysis (73) . Both France and Italy found the total cost of treating patients in the prophylaxis group was significantly higher (around 3.5 times, 3.7-4.1 times for direct costs) than in the OD group, while in Germany prophylaxis group costs were lower than the OD group. Hospitalisation costs were highest in the French OD group (64% of direct There appears to be no significant variation in hospitalisation costs between type A and B haemophilia (91) , but annual treatment costs may vary with age, as German evidence shows paediatric patients, both with and without inhibitors, cost much less to treat than adults (by more than 4 times in both groups) (92) .
Comparing mean and median costs, it is evident some of the high cost cases cause the mean cost to be significantly higher than the cost for a typical patient (77, 78, 82) .
Juvenile idiopathic arthritis
Across the eight costing studies discovered and examined, study perspective, sample size (and mean age) and data reference year varied significantly. Six of the studies examined the economic impact associated JIA, while one study considered the impact on total cost of etanercept treatment (93) and another examined the cost-effectiveness of JIA hydrotherapy (94) ; although these focused primarily on the cost-effectiveness or effect on treatment cost of specific therapies, they are included here because they provide a comparison for standard therapies.
The mean annual total cost is estimated between €4,143/patient (€3,471 in 1999) (95) and €29,613/patient (US$33,171 in 2000) (93, 96) . Substantial variation is evident between sub-groups, however, there is a suggestion that a small proportion of patients (<12%) are responsible for 80% of overall costs, with a small number of inpatient cases accounting for 53% of direct costs (95) . A small proportion of direct cost (3%) were due to devices and aids, and 14% attributable to medications (95) .
Loss of income for parents was generally taken as a measure of indirect costs. In 1999, these costs were estimated at €1,870/patient annually (€1,571 in 1999), 86% of direct costs. In 2008, the same authors reported €274/patient annually (€270 in 2008), 6% of direct cost (95, 96) . This reduction over time may be due to benefits of improved drug Costs at all levels are substantially skewed towards active patients (those not in remission). For example, the mean total cost of active JIA patients at €6,763 (€5,681 in 1999) are more than seven times those in remission at €931 (€782 in 1999) (95) . There is also substantial variation by subgroup with highest costs in patients with enthesitisrelated, systemic JIA, extended oligoarthritis and polyarthritis (RF+ v ) (95, 97) , for whom the total treatment costs are almost double all JIA patients (95) . (93) , where drugs accounted for up to 54% of direct costs. Direct costs in turn account for 6-55% of total costs, depending on the study (95, 96) . In 
Mucopolysaccharidosis type I and type VI (MPS I, MPS VI)
Only one study, a systematic review, was found which detailed costs and effectiveness of 
Scleroderma (systemic sclerosis)
In total four studies were identified that addressed lifetime, direct and/or indirect costs, and one study that quantified specific drugs/therapies. The aggregate annual costs of 
Prader-Willi syndrome
No studies with information on the COI related to PWS were found during the study period.
Histiocytosis
Only one study was identified explicitly quantifying costs of any of the histiocytosis syndromes, focusing on Niemann-Pick disease (NPD) with a comprehensive breakdown of direct (medical and non-medical) and indirect costs (34) . A c c e p t e d M a n u s c r i p t
Epidermolysis Bullosa
Overall, one study was identified that addressed cost-effectiveness aspects of screening and one that discussed specific treatments/therapies. One study examines the cost effectiveness of the 'Kozak protocol' in treating nine children in a single hospital in Ontario, Canada (1980 data) viii (36) . A response to this study by Ramsay (1984) indicates some serious discrepancies in the cost data, specifically which costs from the 9 patients actually pertained to EB (106) . As a result, these costs have not been discussed in any depth. High-dose intravenous immunoglobin (hdIVIg) has been used to treat a few cases of EB, however its clinical efficacy is unclear as this treatment was not undertaken within a controlled trial setting (107) . No other studies were found related to costs and EB. <Table 3 about here> 4. Discussion
Evidence and policy implications
In this review, we identified 77 studies that provide some level of information on the economic burden of ten selected RDs. An overall summary of the cost results is shown in Table 3 . For some conditions (PWS and EB) no COI information was available despite relatively high prevalence (see Table 2 ). For other conditions (DMD, MPS I and VI, histiocytosis, FXS, scleroderma) COI information was very limited, and with the exception of MPS for which rhASB has undergone clinical trials as a treatment, none of the conditions for which little COI evidence was found are associated with a specific pharmaceutical treatment. Rather, care is based on the alleviation of symptoms, management of complications and other supportive care.
In contrast, pharmaceutical compounds are available specifically for CF (DNase) and for haemophilia (clotting factors), which between them account for 47 of the 77 studies included in this review. Overall, the availability of evidence on the economic burden of RDs appears to be correlated with the availability of specific therapies rather than, for instance, the rarity or severity of the disease itself (Figure 2 ).
For the conditions with the most detailed evidence (CF, haemophilia and JIA) there are some common features. The distribution of costs over different patients tends to be skewed with either a small proportion of patients accounting for a large proportion of resource utilisation (82, 95, 96) or particular subgroups of patients incurring higher costs. For example, haemophilia patients with HIV were four times as expensive to treat as HIV negative (85), and seropositive polyarthritis was five times more expensive to treat than persistent oligoarthritis both in total and direct cost estimates for JIA patients (96) .
In most studies reviewed in this study, the median cost tended to be lower than the mean, consistent with a small proportion of high-cost patients driving up average costs therefore suggesting a positive skew. As a summary of economic burden we have reported the mean rather than the median since this better incorporates the variation in severity among patients. When interpreting the results, therefore, it should be taken into account that the typical (median) patient will likely incur lower costs than reported here, while a small number of patients will incur substantially higher costs.
Apart from the direct cost of treatment borne either by insurance organisations or patients and families privately and, in most cases, on an out-of-pocket basis, the indirect COI signifies the burden on the affected patient or carer, and is higher for more debilitating conditions. When comparing the indirect cost to direct cost we find that the former can be significantly higher, e.g. up to 216% of direct costs in the case of scleroderma. All evidence on scleroderma suggests indirect exceeding direct costs (30, 105) , but in all other conditions where evidence is available the indirect costs amount to less than direct costs. In some cases, direct and indirect costs can be traded off against each other, as in haemophilia care, where patients treated prophylactically incur higher direct costs as a result of factor use but avoid more hospitalizations and thus disruptions to their daily life and work pattern (75) . However, most conditions examined here do not have an effective prophylaxis regime, as patients are continually affected by symptoms and must be managed on a regular basis. Importantly we note that evidence on indirect cost was only available for four out of ten diseases, and that the COI from a societal perspective for most of the diseases examined here, therefore, is M a n u s c r i p t 27 not known. As discussed earlier, indirect costs may account for a significant proportion of overall costs and as such this lack of evidence constitutes an important shortfall. The non-availability of COI evidence reflects the rarity of the ten diseases investigated.
In constrast to other disease areas such as cancer and diabetes, the impact of these RDs on patient population and their carers is not well documented. The results of this study suggest that more could be done to study the economic consequences of RDs on society, not only accounting for direct medical costs but also for indirect costs relating to productivity losses given their significant magnitude. At a broader level, these results also point towards the need for society to invest in researching and developing new therapies, and allocating resources to ensure patient access. Nevertheless, it should be borne in mind that such decisions are always associated with important opportunity costs relating to allocation of resources elsewhere, either for the discovery and 
Challenges, limitations and ways forward
A number of methodological questions and limitations need to be raised in connection with the study, its findings and their meaning. Although many of them lie outside the scope of this study they should be acknowledged and earmarked for further investigation. Most of them relate to the comparability of costing evidence across settings, individual disease areas and over time. First, despited having facilitated comparisons across countries and therapeutic areas by harmonising currencies and cost years, one limitation of this study is the wide variety of costing methodologies used, including differences in discounting, assumptions relating to life expectancy and other treatment factors, and differences in the categories of costs included. Indirect costs, largely based on measures of productivity, also differ between studies. This limits the direct comparability of costs between RDs, and, consequently, the use of such information in priority setting. Second, the approach used to compare costs across countries through exchange rate-adjusted currency units does not necessarily address differences in income across countries. Other more advanced approaches, such as adjusting figures to absolute GDP differences and variations in the GDP percentage spent on health across the different countries could be adopted instead, aiding more robust conclusions on the magnitude of costs, their differences and comparability across different settings. A third limitation is the varying discount rates applied when calculating lifetime economic burden. Although in most cases lifetime cost figures are M a n u s c r i p t 29 estimated by considering the respective life expectancy of the disease, varying discount rates can be applied across different studies therefore limiting the comparability of the results. A further limitation is that, strictly speaking, intangible costs relating to suffering of patients and carers are not considered as "costs" but, instead, as quality of life dimensions and, therefore, are not addressed by the current study. Future research might want to adopt a broader perspective and capture these costs to the extent possible. A final limitation is the relatively small sample size in most rare disease COI studies, which in many cases include approximately 100-300 subjects per study but often less than 100 subjects, a corollary of the nature and prevalence of the diseases studied. There was a relatively strong country bias towards the United States and Canada, which accounted for 21 and 9 studies respectively, though Germany, UK, France and Netherlands also accounted for 11, 10, 6 and 5 studies each, respectively ix . The above limitations suggest that future research and priority setting in this area would benefit significantly from a harmonised framework for COI studies, conceptually similar to the Organisation for Economic Cooperation and Development (OECD) System of Health Accounts (109) applied for health systems more broadly. <Figure 2 about here>
Conclusions
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